Profile of Somryst Prescription Digital Therapeutic for Chronic Insomnia: Overview of Safety and Efficacy
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Introduction: Prescription digital therapeutics (PDTs) represent a new class of software-based medical devices authorized by the Food and Drug Administration (FDA) to treat disease. Somryst™, the first PDT for treating chronic insomnia, delivers cognitive behavioral therapy for insomnia (CBT-I) via a mobile application. CBT-I is the guideline-recommended, first-line treatment for chronic insomnia, but availability of CBT-I therapists is limited. Somryst addresses this need by providing asynchronous access to CBT-I treatment. As a contactless therapeutic medium, Somryst is also an ideal option when face-to-face therapy is not available or recommended for safety reasons (e.g. because of possible exposure to the SARS-CoV-2 virus).Areas covered: This review summarizes the mechanisms of action and technical features of Somryst, and describes safety and effectiveness data from the randomized trials on which FDA clearance was based.Expert opinion: Somryst demonstrates robust clinical efficacy with a favorable benefit-to-risk profile for treating adults with chronic insomnia. FDA clearance was based on data from 2 clinical trials of the first-generation web-based CBT-I platform Sleep Healthy Using the Internet (SHUTi). Somryst, and PDTs in general, are promising devices to address the need for greater accessibility to effective therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Validation of the Insomnia Severity Index as an outcome measure for insomnia research
Bastien, C. (2001) · Sleep Medicine · doi:10.1016/s1389-9457(00)00065-4 · Cited by 8,067 · cited 14×
“Additional evidence of the proportion of participants demonstrating a clinically meaningful response based on criteria for SOL and WASO was also significantly higher for the SHUTi treatment group compared with the control group at all time points (Table 1).”
BackgroundMethodInfluentialThe PHQ-8 as a measure of current depression in the general population
Kroenke, K., Strine, T. W., Spitzer, R. L., Williams, J. B. W., Berry, J. T., & Mokdad, A. H. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.06.026 · Cited by 5,121 · cited 1×
“bedtime, time to fall asleep) [40], selfreports of perceived insomnia severity that include both nighttime and daytime components [41], and self-reports of depressive symptoms to screen for daytime impairment of mood [42].”
BackgroundThe International Classification of Sleep Disorders: Diagnostic and Coding Manual
Daroff, R. B. (1991) · Neurology · doi:10.1212/wnl.41.1.160 · Cited by 5,014
Morin, C. M., Belleville, G., Bélanger, L., & Ivers, H. (2011) · Sleep · doi:10.1093/sleep/34.5.601 · Cited by 4,620 · cited 3×
“bedtime, time to fall asleep) [40], selfreports of perceived insomnia severity that include both nighttime and daytime components [41], and self-reports of depressive symptoms to screen for daytime impairment of mood [42].”
BackgroundSelf-citationThe consensus sleep diary: standardizing prospective sleep self-monitoring
Carney, C. E., Buysse, D. J., Ancoli-Israel, S., Edinger, J. D., Krystal, A. D., Lichstein, K. L., & Morin, C. M. (2012) · Sleep · doi:10.5665/sleep.1642 · Cited by 2,172 · cited 3×
“derived sleep metrics (eg, SOL, WASO, frequency of awakenings, total sleep time, sleep efficiency) [40].”
BackgroundSelf-citationQaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2016) · Annals of Internal Medicine · doi:10.7326/m15-2175 · Cited by 1,965 · cited 2×
“Academy of Sleep Medicine and the American College of Physicians [13,14].”
BackgroundClinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults
Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., & Sateia, M. (2008) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27286 · Cited by 1,943 · cited 3×
“Academy of Sleep Medicine and the American College of Physicians [13,14].”
BackgroundSateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
Insomnia: Definition, Prevalence, Etiology, and Consequences
Roth, T. (2007) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.26929 · Cited by 1,492
Research works printed but not linked: 8
- American Academy of Sleep Medicine, 2014, International classification of sleep disorders
- Ancoli-Israel S, 1999, Sleep, 22, S347
- Shore JH, 2020, JAMA Psychiatry
- Morin CM, 1993, Treatment manuals for practitioners
- 10.1001/jamapsychiatry.2016.3249 · DOI · Paper page
- 10.1037/0022-006X.69.1.58 · doi:10.1037/0022-006x.69.1.58 · Paper page
- Center for Devices Radiological Health, 2017, De novo summary for reSET (DEN160018)
- Food and Drug Administration. Guidance for the content of premarket submissions for software contained in medical devices
Cited by
Insomnia disorder: State of the science and challenges for the future
Riemann, D., Benz, F., Dressle, R. J., Espie, C. A., Johann, A. F., Blanken, T. F., Leerssen, J., Wassing, R., Henry, A. L., Kyle, S. D., et al. (2022) · Journal of Sleep Research · doi:10.1111/jsr.13604 · Cited by 343
“Indeed, in the USA, Somryst has been cleared by the FDA as a prescription digital therapeutic (Morin, 2020).”
BackgroundIntroduction of digital therapeutics
Hong, J. S., Wasden, C. L., & Han, D. H. (2021) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2021.106319 · Cited by 184
Lutz, J., Offidani, E., Taraboanta, L., Lakhan, S. E., & Campellone, T. R. (2022) · Frontiers in Digital Health · doi:10.3389/fdgth.2022.823977 · Cited by 89
“Several DTx have been authorized or cleared by the FDA as SaMD (e.g. reSET (8, 45), reSET-O (46), Somryst (5), EndeavorRx (27), Parallel (47)) and several digital health companies have communicated pursuing FDA”
BackgroundDigital therapeutics in the clinic
Phan, P., Mitragotri, S., & Zhao, Z. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10536 · Cited by 104
“had its own limitations as to the nature of its design; it focused on a sleep restriction that may potentially exacerbate other comorbidities such as bipolar disorder in some patients.(52) Another approved DTx product for managing insomnia is NightWareTM, which was also approved for treating PTSD.”
BackgroundOverview of sleep management during COVID-19.
Becker, P. M. (2022) · Sleep Medicine · doi:10.1016/j.sleep.2021.04.024 · Cited by 51
“Online, digital cognitive behavioral therapy may be able to address the multitude in need of intervention for insomnia disorder [29,30].”
BackgroundMethod
Metadata
- Authors
- Morin, C. M.
- Affiliations
- Université Laval (CA)
- Corresponding author
- Morin, Charles M.
- ORCID
- Morin, Charles M.
- Venue
- Expert Review of Medical Devices
- Publisher
- Informa UK Limited
- Published
- 2020-12-01
- Volume
- 17
- Issue
- 12
- Pages
- 1239-1248
- ISSN
- 1743-4440 (ISSN-L)
- 1745-2422
- OpenAlex
- W3108593994
- Cited by
- 66
- References
- 59
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 17 · 2023: 16 · 2022: 10 · 2021: 6
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Expert Review of Medical Devices (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- funded by Pear Therapeutics, Inc
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Social Sciences › Psychology › Applied Psychology › Digital Mental Health Interventions
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Keywords
- prescription digital therapeutics, chronic insomnia, cognitive behavioral therapy for insomnia, mobile application, FDA clearance, treatment efficacy and safety, telemedicine, SARS-CoV-2 exposure
- MeSH terms
- COVID-19, SARS-CoV-2, Chronic Disease, Humans, Sleep Initiation and Maintenance Disorders, Cognitive Behavioral Therapy, Prescriptions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Profile of Somryst Prescription Digital Therapeutic for Chronic Insomnia: Overview of Safety and Efficacy. https://app.cochat.ai/papers/10.1080/17434440.2020.1852929
- The paper
- Morin, C. M. (2020). Profile of Somryst Prescription Digital Therapeutic for Chronic Insomnia: Overview of Safety and Efficacy. Expert Review of Medical Devices. https://doi.org/10.1080/17434440.2020.1852929
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.